Company research
Alector, Inc.
CIK 1653087Updated Nov 16, 2026
ALEC price & chart
Loading TradingView…
NASDAQ:ALEC on TradingView ↗About the company
Alector is a biotechnology company focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. Leveraging the principles of genetics, immunology, and neuroscience, the company is advancing a portfolio of programs that aim to remove toxic proteins, replace missing proteins, and restore immune and nerve cell function. Supported by biomarkers, Alector’s product candidates seek to treat a range of indications, such as Alzheimer’s disease and Parkinson's disease. The company is also developing Alector Brain Carrier (ABC), a proprietary blood-brain barrier platform, which is being applied to its preclinical and research pipeline. ABC aims to enhance the delivery of therapeutics, achieve deeper brain penetration and efficacy at lower doses, and ultimately improve patient outcomes while reducing costs. Alector is headquartered in South San Francisco, California. For more information, please visit www.alector.com.
In the news
Biotech Brainiacs and Breakthroughs ↗
INVESTOR ALERT: Levi & Korsinsky is Investigating Alec Stock After its Phase 3 INFRONT-3 Clinical Trial Misses Co-Primary Endpoint News provided by Levi & Korsinsky, LLP Jan 29, 2026, 18:06 ET Share this article Share to X Share this article Share to X NEW YORK , Jan. 29, 2026 /PRNewswire/ -- Levi & ↗
Recent filings
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
SCHEDULE 13G - filed by RA CAPITAL MANAGEMENT, L.P. regarding Alector, Inc.
424B5 filing
Entry into a Material Definitive Agreement · Other Events
Items 1.01, 8.01, 9.01
Show 5 more recent filings
FWP - filed by Alector, Inc. regarding Alector, Inc.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02
Entry into a Material Definitive Agreement · Results of Operations and Financial Condition · Regulation FD Disclosure · Other Events
Items 1.01, 2.02, 7.01, 8.01, 9.01
144 filing
144 filing
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 335,285,000Source | 516,023,000Source | 202,855,000Source | 356,422,000Source | 570,729,000Source | 239,916,000Source | 408,303,000Source | 635,494,000Source | 293,237,000Source | 468,303,000Source | 621,827,000Source | 787,648,000Source |
| Property, Plant and Equipment, NetUSD | 12,714,000Source | 18,216,000Source | 8,912,000Source | 13,914,000Source | 19,950,000Source | 9,934,000Source | 16,207,000Source | 20,835,000Source | 10,841,000Source | 17,145,000Source | 21,861,000Source | 25,521,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 76,503,000Source | 37,159,000Source | 59,915,000Source | 44,771,000Source | 47,545,000Source | 76,962,000Source | 37,973,000Source | 72,552,000Source | 65,802,000Source | 33,021,000Source | 74,555,000Source | 154,323,000Source |
| Assets, CurrentUSD | 300,385,000Source | 469,364,000Source | 180,087,000Source | 319,178,000Source | 519,701,000Source | 215,084,000Source | 366,650,000Source | 581,390,000Source | 266,452,000Source | 424,817,000Source | 565,807,000Source | 726,435,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 9,277,000Source | 12,162,000Source | 7,289,000Source | 11,898,000Source | 16,367,000Source | 8,569,000Source | 12,099,000Source | 19,307,000Source | 10,428,000Source | 11,420,000Source | 16,946,000Source | 10,997,000Source |
| Operating Lease, Right-of-Use AssetUSD | 15,869,000Source | 20,809,000Source | 11,657,000Source | 16,990,000Source | 23,417,000Source | 12,683,000Source | 19,082,000Source | 24,321,000Source | 13,712,000Source | 19,951,000Source | 25,195,000Source | 27,811,000Source |
| Other Assets, NoncurrentUSD | 4,471,000Source | 6,088,000Source | 353,000Source | 4,494,000Source | 6,115,000Source | 369,000Source | 4,518,000Source | 7,402,000Source | 386,000Source | 4,544,000Source | 7,418,000Source | 6,409,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 277,573,000Source | 397,090,000Source | 212,825,000Source | 285,247,000Source | 420,162,000Source | 229,534,000Source | 313,693,000Source | 456,587,000Source | 262,588,000Source | 341,503,000Source | 487,669,000Source | 573,206,000Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 10,000Source | 9,000Source | 11,000Source | 9,000Source | 9,000Source | 11,000Source | 9,000Source | 9,000Source | 11,000Source | 9,000Source | 8,000Source | 8,000Source |
| Additional Paid in CapitalUSD | 992,294,000Source | 945,046,000Source | 1,008,121,000Source | 971,192,000Source | 936,011,000Source | 1,005,461,000Source | 964,008,000Source | 925,458,000Source | 1,002,528,000Source | 955,657,000Source | 844,044,000Source | 798,696,000Source |
| Retained Earnings (Accumulated Deficit)USD | -934,789,000Source | -827,053,000Source | -1,017,976,000Source | -900,122,000Source | -784,833,000Source | -994,986,000Source | -869,598,000Source | -746,157,000Source | -972,056,000Source | -829,127,000Source | -710,078,000Source | -579,687,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 197,000Source | 931,000Source | -126,000Source | 96,000Source | -620,000Source | -104,000Source | 191,000Source | -403,000Source | 166,000Source | 261,000Source | 184,000Source | -4,575,000Source |
| Stockholders' Equity Attributable to ParentUSD | 57,712,000Source | 118,933,000Source | -9,970,000Source | 71,175,000Source | 150,567,000Source | 10,382,000Source | 94,610,000Source | 178,907,000Source | 30,649,000Source | 126,800,000Source | 134,158,000Source | 214,442,000Source |
| Liabilities and EquityUSD | 335,285,000Source | 516,023,000Source | 202,855,000Source | 356,422,000Source | 570,729,000Source | 239,916,000Source | 408,303,000Source | 635,494,000Source | 293,237,000Source | 468,303,000Source | 621,827,000Source | 787,648,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 79,964,000Source | 142,525,000Source | 34,236,000Source | 84,354,000Source | 147,682,000Source | 40,965,000Source | 109,773,000Source | 164,917,000Source | 69,503,000Source | 125,059,000Source | 177,948,000Source | 93,809,000Source |
| Operating Lease, Liability, CurrentUSD | 8,979,000Source | 8,680,000Source | 9,211,000Source | 8,904,000Source | 8,607,000Source | 9,135,000Source | 8,830,000Source | 8,535,000Source | 9,056,000Source | 8,754,000Source | 8,462,000Source | 8,059,000Source |
| Accounts Payable, CurrentUSD | 4,757,000Source | 5,017,000Source | 2,283,000Source | 2,217,000Source | 4,375,000Source | 1,423,000Source | 2,326,000Source | 4,586,000Source | 1,691,000Source | 2,215,000Source | 3,775,000Source | 4,189,000Source |
| Operating Lease, Liability, NoncurrentUSD | 19,285,000Source | 25,959,000Source | 13,699,000Source | 21,043,000Source | 27,506,000Source | 15,646,000Source | 22,754,000Source | 29,022,000Source | 17,488,000Source | 24,376,000Source | 30,456,000Source | 35,268,000Source |
| Other Liabilities, NoncurrentUSD | 1,444,000Source | 1,234,000Source | 2,024,000Source | 1,444,000Source | 1,234,000Source | 1,770,000Source | 1,394,000Source | 1,373,000Source | 1,737,000Source | 1,234,000Source | 1,373,000Source | 759,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 18,332,000Source | 25,696,000Source | 7,036,000Source | 14,215,000Source | 23,081,000Source | 10,931,000Source | 17,320,000Source | 19,385,000Source | 19,299,000Source | 28,890,000Source | 30,378,000Source | 27,771,000Source |
| Long-term Debt, Excluding Current Maturities | — | — | — | — | — | — | — | — | —Source | —Source | — | — |
| Long-term Debt, Excluding Current MaturitiesUSD | 9,611,000Source | — | 0Source | 9,536,000Source | — | 8,287,000Source | 9,464,000Source | — | 9,323,000Source | 9,389,000Source | — | — |
| Long-term Debt, Current Maturities | — | — | —Source | — | — | — | — | — | — | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | -22,930,000Source | -40,471,000Source | -142,929,000Source | -119,049,000Source | -130,391,000Source | -133,310,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation and amortization | — | — | — | — | — | — | —Source | —Source | —Source | —Source | —Source | —Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 2,908,000Source | 8,351,000Source | 26,658,000Source | 39,463,000Source | 42,798,000Source | 46,146,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | -268,000Source | 111,000Source | -524,000Source | -1,441,000Source | -377,000Source | -572,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -49,813,000Source | -60,783,000Source | -184,031,000Source | -229,905,000Source | -184,162,000Source | -20,329,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 60,948,000Source | 65,735,000Source | 196,597,000Source | 107,131,000Source | 101,918,000Source | -159,014,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 118,000Source | 20,000Source | 41,000Source | 1,255,000Source | 2,381,000Source | 4,117,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 25,000Source | 0Source | 20,215,000Source | 81,540,000Source | 2,550,000Source | 4,514,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | 11,160,000Source | 4,952,000Source | 32,781,000Source | -41,234,000Source | -79,694,000Source | -174,829,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 78,349,000Source | 38,705,000Source | 61,761,000Source | 46,617,000Source | 78,808,000Source | 39,819,000Source | 67,648,000Source | 34,867,000Source | 76,101,000Source | 155,795,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | 201,000Source | 214,000Source | 855,000Source | — | — | — |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | -880,000Source | — | — | — |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 6,402,000Source | 9,035,000Source | 2,610,000Source | 7,062,000Source | 2,908,000Source | 8,351,000Source | 26,658,000Source | 39,463,000Source | 42,798,000Source | 46,146,000Source |
| Amortization of Debt Issuance Costs and DiscountsUSD | — | — | — | — | — | — | 78,000Source | 69,000Source | 293,000Source | — | — | — |
| Gain (Loss) on Disposition of AssetsUSD | — | — | — | — | — | — | — | — | — | 0Source | -48,000Source | — |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| General and Administrative ExpenseUSD | — | — | 11,518,000Source | 15,778,000Source | 8,253,000Source | 14,401,000Source | 8,108,000Source | 14,728,000Source | 53,987,000Source | 59,615,000Source | 56,687,000Source | 61,033,000Source |
| Income Tax Expense (Benefit)USD | — | — | 0Source | 0Source | 130,000Source | 0Source | 0Source | 0Source | 168,000Source | 128,000Source | 5,212,000Source | 3,254,000Source |
| Marketable Securities, Unrealized Gain (Loss)USD | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -34,667,000Source | -42,220,000Source | -22,990,000Source | -30,524,000Source | -22,930,000Source | -40,471,000Source | -142,929,000Source | -119,049,000Source | -130,391,000Source | -133,310,000Source |
| Operating ExpensesUSD | — | — | 40,868,000Source | 63,776,000Source | 27,713,000Source | 42,012,000Source | 25,965,000Source | 48,369,000Source | 177,052,000Source | 245,555,000Source | 248,802,000Source | 271,451,000Source |
| Operating Lease, Impairment LossUSD | — | — | — | — | — | — | — | — | 2,922,000Source | 2,205,000Source | — | 0Source |
| Other Nonoperating Income (Expense)USD | — | — | 2,941,000Source | 6,214,000Source | 1,533,000Source | 3,614,000Source | 1,989,000Source | 4,224,000Source | 13,246,000Source | 26,076,000Source | 26,561,000Source | 7,778,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | — | 19,983,000Source | — | — | — |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | 25,000Source | 0Source | 15,000Source | 0Source | 1,079,000Source | 3,059,000Source |
| Restructuring CostsUSD | — | — | — | — | — | — | — | — | 7,300,000Source | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 3,260,000Source | 15,342,000Source | 3,320,000Source | 7,874,000Source | 1,046,000Source | 3,674,000Source | 21,045,000Source | 100,558,000Source | 97,062,000Source | 133,617,000Source |
| Operating Income (Loss)USD | — | — | -37,608,000Source | -48,434,000Source | -24,393,000Source | -34,138,000Source | -24,919,000Source | -44,695,000Source | -156,007,000Source | -144,997,000Source | -151,740,000Source | -137,834,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 2,941,000Source | 6,214,000Source | 1,533,000Source | 3,614,000Source | 1,989,000Source | 4,224,000Source | 13,246,000Source | 26,076,000Source | 26,561,000Source | 7,778,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -34,667,000Source | -42,220,000Source | -22,860,000Source | -30,524,000Source | -22,930,000Source | -40,471,000Source | -142,761,000Source | -118,900,000Source | — | — |
| Income Tax Expense (Benefit)USD | — | — | 0Source | 0Source | 130,000Source | 0Source | 0Source | 0Source | 168,000Source | 128,000Source | 5,212,000Source | 3,254,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -34,667,000Source | -42,220,000Source | -22,990,000Source | -30,524,000Source | -22,930,000Source | -40,471,000Source | -142,929,000Source | -119,049,000Source | -130,391,000Source | -133,310,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.34Source | -0.43Source | -0.21Source | -0.3Source | -0.21Source | -0.41Source | -1.39Source | -1.23Source | -1.56Source | -1.62Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.34Source | -0.43Source | -0.21Source | -0.3Source | -0.21Source | -0.41Source | -1.39Source | -1.23Source | -1.56Source | -1.62Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 102,597,601Source | 97,519,595Source | 111,224,116Source | 100,371,632Source | 110,590,014Source | 99,398,200Source | 102,998,978Source | 96,588,177Source | 83,733,730Source | 82,467,587Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 102,597,601Source | 97,519,595Source | 111,224,116Source | 100,371,632Source | 110,590,014Source | 99,398,200Source | 102,998,978Source | 96,588,177Source | 83,733,730Source | 82,467,587Source |
| Additional Financial Items | ||||||||||||
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | — | — | — | — | 1,081,000Source | 984,000Source | 5,718,000Source | 5,407,000Source | 5,725,000Source | 5,714,000Source |
| General and Administrative ExpenseUSD | — | — | 11,518,000Source | 15,778,000Source | 8,253,000Source | 14,401,000Source | 8,108,000Source | 14,728,000Source | 53,987,000Source | 59,615,000Source | 56,687,000Source | 61,033,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | -34,667,000Source | -42,220,000Source | — | -30,524,000Source | — | -40,471,000Source | -142,761,000Source | -118,921,000Source | -125,179,000Source | -130,056,000Source |
| Labor and Related ExpenseUSD | — | — | 13,036,000Source | 18,405,000Source | 7,067,000Source | 14,262,000Source | 8,248,000Source | 16,557,000Source | 51,783,000Source | 73,200,000Source | — | — |
| Operating ExpensesUSD | — | — | 40,868,000Source | 63,776,000Source | 27,713,000Source | 42,012,000Source | 25,965,000Source | 48,369,000Source | 177,052,000Source | 245,555,000Source | 248,802,000Source | 271,451,000Source |
| Research and Development ExpenseUSD | — | — | 29,350,000Source | 47,998,000Source | 19,460,000Source | 27,611,000Source | 17,857,000Source | 33,641,000Source | 123,065,000Source | 185,940,000Source | 192,115,000Source | 210,418,000Source |
| Restructuring CostsUSD | — | — | — | — | — | — | — | — | 7,300,000Source | — | — | — |
Filing attachments
alec-ex99_1.htm · 8-K · 2026-11-05
Exhibit 99.1 Alector Reports Third Quarter 2026 Financial Results and Provides Business Update Advancing a pipeline built entirely on the Alector Brain Carrier (ABC) blood-brain barrier platform, spanning antibody, enzyme, and siRNA programs, with AL137, Alector's lead ABC-enabled anti-amyloid beta (Aβ) antibody program for Alzheimer's disease (AD), targeting first-in-human dosing in Australia no later than April 2027. Continued progress across AL164 (ABC-enabled Tau siRNA for AD and other ta…
Read attachment ↗d417912dex991.htm · 8-K · 2026-10-16
Exhibit 99.1 RELEASE Alector Announces Pricing of Underwritten Offering SOUTH SAN FRANCISCO, Calif., October 16, 2026 (GLOBE NEWSWIRE) - Alector, Inc. (“Alector,” Nasdaq: ALEC), a biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced the pricing of an underwritten offering of common stock. Alector is selling 36,600,000 shares of common stock. The shares of common stock are being sold at an offering price of $2.0…
Read attachment ↗alec-ex99_1.htm · 8-K · 2026-08-06
EX-99.1 2 alec-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Alector Reports Second Quarter 2026 Financial Results and Provides Business Update Advancing the Alector Brain Carrier (ABC) blood-brain barrier platform across antibodies, enzymes, and siRNA, with AL137 advancing as Alector’s lead ABC-enabled anti-amyloid beta (Aβ) antibody program for Alzheimer’s disease (AD). Continued progress across AL064/AL164 (ABC-enabled Tau siRNA for AD and other tauopathies) and AL050 (ABC-enabled GCase Enz…
Read attachment ↗alec-ex99_1.htm · 8-K · 2026-05-07
EX-99.1 2 alec-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Alector Reports First Quarter 2026 Financial Results and Provides Business Update Advancing the Alector Brain Carrier (ABC) platform across multiple therapeutic modalities, including antibodies, enzymes, and siRNA, with continued progress across AL037/AL137 (ABC-enabled antibody for Alzheimer’s disease (AD)), AL050 (ABC-enabled GCase Enzyme Replacement Therapy for Parkinson’s disease (PD)), and AL064/AL164 (ABC-enabled Tau siRNA for A…
Read attachment ↗